Does Needle Design Affect the Regenerative Potential of Bone Marrow Aspirate? An In Vitro Study

Nadia Feddahi; Monika Herten; Tjark Tassemeier; Heike Rekasi; Alexander Hackel; Marcel Haversath; Marcus Jäger

doi:10.3390/life11080748

Does Needle Design Affect the Regenerative Potential of Bone Marrow Aspirate? An In Vitro Study

Life (Basel). 2021 Jul 26;11(8):748. doi: 10.3390/life11080748.

Authors

Nadia Feddahi¹, Monika Herten², Tjark Tassemeier³, Heike Rekasi¹, Alexander Hackel^{4

5}, Marcel Haversath^{1

6}, Marcus Jäger^{7

8}

Affiliations

¹ Department of Orthopedic and Trauma Surgery, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45147 Essen, Germany.
² Clinic of Trauma, Hand and Reconstructive Surgery, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45147 Essen, Germany.
³ Department of Orthopedic, Gelenkzentrum Bergisch Land, Freiheitstraße 203, D-42853 Remscheid, Germany.
⁴ Department of Otorhinolaryngology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, D-45147 Essen, Germany.
⁵ Department of Rheumatology and Clinical Immunology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany.
⁶ Department of Orthopedic, St. Vinzenz Krankenhaus Düsseldorf, Schloßstraße 85, D-40477 Düsseldorf, Germany.
⁷ Department of Trauma, Reconstruction and Orthopedic Surgery, St. Marien Hospital, Mülheim an der Ruhr, Kaiserstraße 50, D-45468 Mülheim an der Ruhr, Germany.
⁸ Orthopedics and Trauma Surgery, University of Duisburg Essen, D-45147 Essen, Germany.

Abstract

While autologous bone is still the gold standard for treatment of bone defects, its availability is limited. Sufficient numbers of mesenchymal stroma cells (MSC) may be an alternative. Small volumes of bone marrow aspirate (BMA) were harvested with two different needle systems comparing the yield and regenerative potency of the MSCs. BMA (10 mL) was aspirated from the posterior iliac crest of 12 patients with degenerative spinal disc disease using both needle systems in each patient: the Jamshidi needle (JAM) and on the contralateral side the Marrow Cellution^® Needle (AMC). Number of mononuclear cells (MNCs) and regeneration capacity (colony-forming unit/CFU) were determined. MSCs were characterized for surface markers and their differentiation into trilineages. There was no significant difference between the two harvesting needles regarding the quantity of MNCs in BMA: 5.2 ± 1.8 × 10⁹ MNC/mL for AMC vs. 4.8 ± 2.5 × 10⁹ MNC/mL for JAM, p = 0.182. The quantity of CFUs per ml BMA was similar for both groups: 3717 ± 5556 for AMC and 4305 ± 5507 for JAM (p = 0.695). The potency of MSCs expressed as colony-forming potential per 10⁶ MNC resulted in 0.98 ± 1.51 for AMC and 1.00 ± 0.96 for JAM (p = 0.666). Regardless of the needle design, 10 mL bone marrow aspirate contains a sufficient number of about 40,000 MSCs that can be used to enhance bone healing.

Keywords: Aspire Marrow Cellution®; Jamshidi needle; bone healing; bone marrow aspirate; bone marrow aspirate concentrate; mesenchymal stem cells.